Primate immunodeficiency virus Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex [preprint] by Yurkovetskiy, Leonid et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2018-04-03 
Primate immunodeficiency virus Vpx and Vpr counteract 
transcriptional repression of proviruses by the HUSH complex 
Leonid Yurkovetskiy 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Hemic and Immune Systems Commons, Immune System Diseases Commons, 
Immunology of Infectious Disease Commons, Molecular Biology Commons, Virology Commons, Virus 
Diseases Commons, and the Viruses Commons 
Repository Citation 
Yurkovetskiy L, Guney MH, Kim K, Goh SL, McCauley SM, Dauphin A, Diehl WE, Luban J. (2018). Primate 
immunodeficiency virus Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH 
complex. University of Massachusetts Medical School Faculty Publications. https://doi.org/10.1101/
293001. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/1515 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
  
  





Primate  immunodeficiency  virus  Vpx  and  Vpr  counteract  









Leonid  Yurkovetskiy1,  Mehmet  Hakan  Guney1,  Kyusik  Kim1,  Shih  Lin  Goh1,  Sean  
McCauley1,  Ann  Dauphin1,  William  Diehl1,  and  Jeremy  Luban1,2*  
    








1Program   in   Molecular   Medicine,   University   of   Massachusetts   Medical   School,  
Worcester,  MA  01605,  USA  
  
2Department  of  Biochemistry  and  Molecular  Pharmacology,  University  of  Massachusetts  





*Correspondence:  jeremy.luban@umassmed.edu  (J.L.)  
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/293001doi: bioRxiv preprint first posted online Apr. 3, 2018; 
   1  
Drugs   that   inhibit   HIV-­1   replication   and   prevent   progression   to   AIDS   do   not  1  
eliminate  HIV-­1  proviruses  from  the  chromosomes  of   long-­lived  CD4+  memory  T  2  
cells.   To   escape   eradication   by   these   antiviral   drugs,   or   by   the   host   immune  3  
system,   HIV-­1   exploits   poorly   defined   host   factors   that   silence   provirus  4  
transcription.  These  same  factors,  though,  must  be  overcome  by  all  retroviruses,  5  
including  HIV-­1  and  other  primate  immunodeficiency  viruses,  in  order  to  activate  6  
provirus   transcription  and  produce  new  virus.  Here  we  show   that  Vpx  and  Vpr,  7  
proteins   from   a   wide   range   of   primate   immunodeficiency   viruses,   activate  8  
provirus   transcription   in   human   CD4+   T   cells.   Provirus   activation   required   the  9  
DCAF1  adaptor  that  links  Vpx  and  Vpr  to  the  CUL4A/B  ubiquitin  ligase  complex,  10  
but   did   not   require   degradation   of   SAMHD1,   a   well-­characterized   target   of   Vpx  11  
and  Vpr.  A   loss-­of-­function  screen   for   transcription  silencing   factors   that  mimic  12  
the   effect   of   Vpx  on  provirus   silencing   identified   all   components   of   the  Human  13  
Silencing  Hub  (HUSH)  complex,  FAM208A  (TASOR/RAP140),  MPHOSPH8  (MPP8),  14  
PPHLN1   (PERIPHILIN),   and   MORC2.   Vpx   associated   with   the   HUSH   complex  15  
components   and   decreased   steady-­state   levels   of   these   proteins   in   a   DCAF-­16  
dependent  manner.  Finally,  vpx  and  FAM208A  knockdown  accelerated  HIV-­1  and  17  
SIVMAC  replication  kinetics  in  CD4+  T  cells  to  a  similar  extent,  and  HIV-­2  replication  18  
required   either  vpx   or   FAM208A  disruption.   These   results   demonstrate   that   the  19  
HUSH  complex   restricts   transcription  of   primate   immunodeficiency   viruses   and  20  
thereby   contributes   to   provirus   latency.   To   counteract   this   restriction   and  21  
activate  provirus  expression,  primate  immunodeficiency  viruses  encode  Vpx  and  22  
Vpr  proteins  that  degrade  HUSH  complex  components.  23  
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When  provided  in  trans,  many  primate  immunodeficiency  virus  Vpx  and  Vpr  orthologues  24  
increase   HIV-­1   reverse   transcription   and   transduction   efficiency   in   dendritic   cells,  25  
macrophages,  and  resting  CD4+  T  cells  (Baldauf  et  al.,  2012;;  Goujon  et  al.,  2006;;  Lim  et  26  
al.,  2012;;  Sharova  et  al.,  2008;;  Srivastava  et  al.,  2008).  As  substrate  adaptor  proteins  27  
for  the  DCAF1-­CUL4A/B  E3  ubiquitin  ligase,  Vpx  and  Vpr  increase  the  concentration  of  28  
deoxynucleotide   triphosphate   (dNTP)   levels   in   target   cells   by   degrading   the  29  
deoxynucleotidetriphosphate  (dNTP)  hydrolase  SAMHD1  (Hrecka  et  al.,  2011;;  Laguette  30  
et   al.,   2011;;   Lim   et   al.,   2012).   Nonetheless,   Vpx   and   Vpr   have   additional   effects   on  31  
expression   of   transduced   reporter   genes   that   are   not   explained   by   SAMHD1  32  
degradation  or  by  increase  in  dNTP  concentration  (Goh  et  al.,  1998;;  Miller  et  al.,  2017;;  33  
Pertel  et  al.,  2011a;;  Reinhard  et  al.,  2014).  34  
To  better   understand   the  effect   on  provirus   reporter   gene  expression,  vpx  was  35  
introduced  before,  during,  or  after  transduction  of  a  reporter  gene  (Fig.  1a).  Jurkat  CD4+  36  
T   cells  were   transduced  with   a   dual-­promoter,   lentiviral   vector   that   expresses   codon-­37  
optimized   SIVMAC251   vpx   from   the   spleen   focus   forming   virus   (SFFV)   promoter   and  38  
puromycin   acetyltransferase   (puroR)   from   the   PPIA   (CypA)   promoter   (Neagu   et   al.,  39  
2009;;  Reinhard  et  al.,  2014)  (Lenti  1  in  the  Fig.  1a  time-­line,  Supplementary  Fig.  1a,  and  40  
Supplementary   Table   1).   A   control   Lenti   1   vector   was   used   that   lacks   vpx  41  
(Supplementary   Fig.   1a).   Puromycin  was   added   to   the   culture   on   day   three   to   select  42  
those  cells  that  had  been  transduced  with  Lenti  1.  On  day  seven,  cells  were  transduced  43  
with  a  second   lentivector  bearing  a  codon-­optimized  gag-­gfp   reporter  gene  expressed  44  
from  the  SFFV  promoter,  as  well  as  SIVMAC251  vpx  expressed  from  the  CypA  promoter  45  
(Lenti  2  in  the  Fig.  1a  timeline  and  Supplementary  Fig.1a).  A  control  Lenti  2  vector  was  46  
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used   that   lacks   vpx   (Supplementary   Fig.1a).   On   day   ten,   virus-­like   particles   (VLPs)  47  
containing  Vpx  protein  were  added  to  the  twice-­transduced  cells  (Fig.  1a).  As  controls,  48  
VLPs   lacking  Vpx  were   used,   or   no  VLPs  were   added.  On  day   fourteen,   the   percent  49  
GFP+  cells  under  each  condition  was  assessed  by  flow  cytometry  using  standard  gating  50  
for   viable,   singlet,   lymphoid   cells   (Supplementary   Figure   1b).   Vpx   increased   the  51  
percentage   of   GFP+   cells,   whether   vpx   was   transduced   before,   or   concurrent   with,  52  
reporter  gene  transduction,  or  if  Vpx  protein  was  delivered  by  VLPs  after  reporter  gene  53  
transduction   (Fig.   1b   and  Supplementary  Fig   1c;;   n=3  biological   replicates,   p<0.02,   1-­54  
way  ANOVA  with  Dunnett  post-­test).  These  results  suggest  that  the  transduced  reporter  55  
gene  was  actively  silenced  and  that  vpx  overcame  reporter  silencing.  56  
To   confirm   that   the   findings   in   Fig.   1b   were   due   to   effects   of   vpx   on  57  
transcriptional   silencing   of   the   reporter   gene,   and   not   due   to   effects   on   transduction  58  
efficiency,   Jurkat   T   cells   were   first   transduced   with   a   vector   in   which   the   gag-­gfp  59  
reporter   gene   was   expressed   from   the   SFFV   promoter   and   blasticidin-­S   deaminase  60  
(blastiR)  was  expressed  from  the  CypA  promoter.  Four  days  after  transduction  with  the  61  
reporter   vector   and   selection   with   blasticidin,   cells   were   either   challenged   with   Vpx+  62  
VLPs,  or  transduced  and  selected  with  the  dual-­promoter  lentivector  encoding  vpx  and  63  
puroR   (Lenti   1   in   Supplementary   Fig.   1a).   Four   days   later   the   GFP   signal   was   at  64  
background   levels   unless   Vpx   was   provided,   either   by   VLPs   (Fig.   1c)   or   by   vpx  65  
transduction  (Fig.  1d).  The  effect  of  vpx  on  reporter  gene  expression  was  confirmed  by  66  
qRT-­PCR  for  the  reporter  mRNA  (Supplementary  Fig.  1d).  Reporter  gene  silencing  and  67  
reactivation  by  Vpx  was  not  specific  to  the  SFFV  promoter  since  GFP  signal  was  similar  68  
when   the   reporter   gene  was  expressed   from   the  human  EEF1A1   (EF1α)  promoter  or  69  
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from  the  Herpes  simplex  virus   type  1   thymidine  kinase  (TK)  promoter   (Supplementary  70  
Fig.  1e).  These  results  demonstrate  that  Vpx  overcomes  transcriptional  silencing  of  the  71  
provirus.  72  
To   determine   if   the   ability   to   activate   transcription   of   silenced   proviruses   is  73  
peculiar   to   SIVMAC251   Vpx,   representative   Vpx   and   Vpr   orthologues,   selected   from  74  
across   the   phylogeny   of   primate   immunodeficiency   viruses,   were   examined.   All   Vpx  75  
proteins   tested,   SIVDRLD3,   SIVRCMNG411,   SIVAGI00CM312,   SIVRCM02CM8081,  76  
SIVMND25440,   HIV-­2ROD,   SIVMAC251,   and   SIVMNE027,   had   transactivating   activity   in  77  
human  cells  (Fig.  1e  and  Supplementary  Fig  1f).  Conservation  of  this  activity  in  human  78  
cells   among   such   divergent   SIV   orthologues  was   surprising   given   that   SIVRCMNG411  79  
Vpx  and  SIVMND25440  Vpx  do  not  degrade  human  SAMHD1,  but   they  do  degrade   the  80  
SAMHD1  orthologue  from  their  cognate  primate  host  species  (Lim  et  al.,  2012).  Several  81  
Vprs  from  SIVs  that  lack  Vpx,  including  SIVMUS2CM1246,  SIVAGMVer9063,  SIVAGMTAN1,  82  
SIVMND1GB1,   and  SIVLST524,   also   activated   transcription   of   silent   proviral   reporters   in  83  
human  cells   (Fig.  1e  and  Supplementary  Fig.  1f).  Results  could  not  be  obtained   from  84  
this  experimental  system  concerning  the  activity  of  Vprs  encoded  by  SIVCPZTAN3,  HIV-­85  
1U14788   (Group   P),   SIVGORCP684con,   HIV-­1MVP5180   (Group   O),   HIV-­1NL4-­3   (Group   M),  86  
SIVCPZLB7,  and  SIVRCM02CM8081,  presumably  because  these  orthologues  caused  cell  87  
cycle  arrest  and  toxicity  (Chang  et  al.,  2004;;  Goh  et  al.,  1998;;  He  et  al.,  1995;;  Re  et  al.,  88  
1995)  (indicated  by ∅  in  Fig.  1e).  Vpx  and  Vpr  sequence  variability  is  among  the  highest  89  
observed  for  lentiviral  coding  sequences  (McCarthy  and  Johnson,  2014);;  the  sequences  90  
shown  in  Fig.  1e  have  an  average  amino  acid  identity  of  only  27%.  Such  diversity  likely  91  
reflects  rapidly  evolving,  host-­pathogen  interfaces  (Fregoso  et  al.,  2013),  and  precluded  92  
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activity   predictions   based   on   amino   acid   sequence   conservation   to   guide   the  93  
engineering  of  loss-­of-­function  mutations.  94  
To   gain   insight   into   the   mechanism   by   which   Vpx   overcomes   transcriptional  95  
silencing  of   lentiviral   transgenes,  a   loss-­of-­function  screen  was  performed   focusing  on  96  
genes  reported  to  contribute  to  silencing  of  retroviruses  and  other  transcriptional  targets  97  
(Chéné  et  al.,  2007;;  Peterlin  et  al.,  2017;;  Tchasovnikarova  et  al.,  2015,  2017;;  Wang  and  98  
Goff,   2017;;   Weinberg   and   Morris,   2016;;   Wolf   and   Goff,   2007).   Jurkat   T   cells   were  99  
transduced   with   lentivectors   that   confer   puromycin   resistance   and   express   shRNAs  100  
(Pertel   et   al.,   2011b)   targeting   either   AGO1,   AGO2,   AGO3,   DNMT3A,   HDAC1,   HP1,  101  
SUV39H1,  SUV39H2,  PIWIL2,  TRIM28,  SETDB1,  FAM208A,  MPHOSPH8,  PPHLN1,  or  102  
MORC2.   After   selection   for   five   days  with   puromycin,   cells   were   transduced  with   the  103  
Lenti  2  gag-­gfp  reporter  vector  without  vpx  (Supplementary  Fig.  1a).  Four  days  later,  the  104  
change   in  expression  of   the  gfp   reporter  due   to   the  knockdowns  was  calculated  as  a  105  
percentage  of  the  activity  observed  in  a  separate  population  of  Jurkat  cells  transduced  106  
to   express   vpx   (Fig.   2a).   A   given   gene   was   implicated   as   a   transcriptional   silencing  107  
factor   for   the   provirus   reporter   gene   if   the   three   shRNA   targets   for   that   gene  differed  108  
significantly  from  that  of  the  luciferase  knockdown  control  (p<0.05,  1-­way  ANOVA  with  109  
Dunnett  post-­test).  shRNAs  targeting  each  of  the  three  core  components  of  the  Human  110  
Silencing   Hub   (HUSH)   complex,   FAM208A,   MPHOSPH8,   and   PPHLN1,   increased  111  
reporter  gene  expression  (Fig.  2a).  112  
The   effect   on   reporter   gene   expression   in   Jurkat   T   cells   of   the  most   effective  113  
shRNA  target  sequences  for  FAM208A,  MPHOSPH8,  and  PPHLN1  is  shown  in  Fig.  2b.  114  
The   effectiveness   of   the   knockdown   of   each   of   the   HUSH   complex   components   in  115  
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Jurkat   cells   was   confirmed   by   immunoblotting   lysate   from   these   cells   with   antibodies  116  
specific   for   FAM208A,   PPHLN1,   or   MPHOSPH8   (Fig.   2c).   As   previously   reported  117  
(Tchasovnikarova  et  al.,  2015),  knockdown  of  any  individual  HUSH  complex  component  118  
caused   a   decrease   in   the   level   of   each   of   the   other   components.   Similar   results   on  119  
reporter   gene   expression   were   obtained   when   FAM208A,   MPHOSPH8,   or   PPHLN1  120  
were  knocked  down  in  primary  human  CD4+  T  cells  (Fig.  2d).  Knockdown  of  each  of  the  121  
HUSH   complex   components,   then,   had   the   same   effect   as   vpx   on   lentiviral   reporter  122  
gene  expression  (Fig.  2b  and  d  and  Supplementary  Fig  2a).  These  results  demonstrate  123  
that  the  HUSH  complex  is  critical  for  provirus  silencing  and  raise  the  possibility  that  Vpx  124  
acts  as  a  substrate  adaptor   targeting  HUSH  components   to  DCAF1  and  the  CUL4A/B  125  
E3  ubiquitin  ligase  complex  for  degradation,  in  the  same  way  that  Vpx  targets  SAMHD1  126  
(Hrecka  et  al.,  2011;;  Laguette  et  al.,  2011).  127  
To  determine   if  Vpx   promotes   the   degradation   of  HUSH  complex   components,  128  
lysate  from  cells  transduced  to  express  SIVMAC251,  SIVMND25440,  or  SIVRCMNG411  vpx  129  
was  immunoblotted  with  antibodies  specific  for  FAM208A,  PPHLN1,  or  MPHOSPH8.  All  130  
three   Vpx   proteins   reduced   the   steady-­state   level   of   all   three   core   HUSH   complex  131  
components  (Fig.  2e).  Among  the  three  HUSH  components,  though,  FAM208A  protein  132  
levels   were   decreased   more   than   the   other   two   components   (Fig.   2f)   so   ongoing  133  
experiments  focused  on  the  effect  of  Vpx  on  FAM208A.  Indeed,  in  addition  to  the  three  134  
Vpx   proteins   assessed   in  Fig.   2e,   the   other  Vpx   and  Vpr   orthologues   shown   to   have  135  
transactivation  activity   in  Fig  1e  and  Supplementary  Fig  1f   (HIV-­2ROD  Vpx,  SIVMNE027  136  
Vpx,      SIVDRLD3   Vpx,   SIVAGMTAN1   Vpr,   SIVMND1GB1   Vpr,   and   SIVLST524   Vpr)   all  137  
decreased  the  levels  of  FAM208A  (Supplementary  Figs.  2b  and  c).    138  
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To  assess  whether  disruption  of  FAM208A  protein  levels  by  Vpx  was  dependent  139  
upon  the  DCAF1  adaptor   for   the  CUL4A/B  ubiquitin   ligase  complex,  as   is   the  case  for  140  
SAMHD1  (Sharova  et  al.,  2008;;  Srivastava  et  al.,  2008),  Jurkat  T  cells  were  transduced  141  
with   a   lentivector   that   knocks   down   DCAF1   (Pertel   et   al.,   2011a),   or   with   a   control  142  
knockdown  vector.  After  selection  with  puromycin  the  cells  were  exposed  for  18  hrs  to  143  
SIV   VLPs   bearing   Vpx,   control   VLPs   that   lacked   Vpx,   or   no   VLPs.   In   the   DCAF1  144  
knockdown   cells,   FAM208A   protein   levels   were   unchanged   by   Vpx,   indicating   that  145  
FAM208A  disruption  by  Vpx  was  dependent  upon  DCAF1  (Fig.  2g).  146  
Degradation  of  SAMHD1   requires  direct   interaction  with  Vpx  or  Vpr   (Lim  et  al.,  147  
2012).  To  determine  if  Vpx  similarly  associates  with  proteins  of  the  HUSH  complex,  HA-­148  
tagged  FAM208A  was  co-­transfected   into  HEK293  cells  with  FLAG-­tagged  SIVMAC251  149  
Vpx   or   SIVRCM02CM8081   Vpx.   When   anti-­FLAG   antibody   was   used   to  150  
immunoprecipitate   either   of   the   two   Vpx   proteins   from   the   soluble   cell   lysate,   HA-­151  
FAM208A   was   detected   in   the   immunoprecipitate   (Fig.   2h).   The   strength   of   the  152  
FAM208A  signal   in   the  Vpx  pull-­out   increased  when   the   co-­transfected  HEK293   cells  153  
were  incubated  with  the  proteasome  inhibitor  PR171,  or  when  wild-­type  SIVMAC251  Vpx  154  
was  replaced  in  the  transfection  by  a  mutant  (Q76A)  that  is  incapable  of  binding  DCAF1  155  
(Pertel  et  al.,  2011a;;  Srivastava  et  al.,  2008)   (Fig.  2h  and  Supplementary  Figs.  2d,e).  156  
These  results  demonstrate  that  FAM208A  associates  with  Vpx  and  that  the  interaction  157  
results  in  proteasome-­mediated  degradation  of  FAM208A.  158  
The  experiments  described  above  examined   the  effect   of  Vpx  or  Vpr  on  HIV-­1  159  
proviruses   in   which   the   reporter   gene   was   transcribed   by   a   heterologous   promoter,  160  
either  human  EF1α,  HSV  TK,  or  the  SFFV  LTR  (Figs  1  and  2,  and  Supplementary  Fig.  161  
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1).  To  determine  if  Vpx  is  capable  of  activating  a  reporter  gene  driven  by  the  HIV-­1  LTR,  162  
the  TNFα-­responsive,   J-­Lat  A1   clonal   cell   line  was  used   (Jordan  et   al.,   2003).   In   this  163  
experimental  model  of  provirus  latency,  the  HIV-­1  LTR  drives  expression  of  a  bicistronic  164  
mRNA   encoding   tat   and   gfp   (Fig.   3a).   Transduction   with   a   lentivector   expressing  165  
SIVmac251  Vpx,  or  knockdown  of  FAM208A,  caused  comparable  increase  in  the  percent  166  
GFP+  J-­Lat  A1  cells,  whether  the  cells  were  stimulated  with  TNFα  or  not  (Fig.  3b  and  c).  167  
Transduction   of   the   J-­Lat   A1   cell   line   with   lentivectors   expressing   vpx   encoded   by  168  
SIVRCM02CM8081   or   SIVMND25440,   as   well   as   with   vpr   encoded   by   SIVMND1GB1   or  169  
SIVAGMTAN1,   caused   similar   increase   in   expression   of   the   LTR-­driven   reporter   gene  170  
(Supplementary  Fig  3a).  171  
J-­Lat  A1  was  selected  to  have  a  silent  HIV-­1  LTR-­driven  provirus  with  the  ability  172  
to   reactivate   in   response   to  TNFα   (Jordan  et   al.,   2003).  The  unique  provirus  within  a  173  
clone  such  as  J-­Lat  A1  may  be  sensitive  to  position-­dependent  silencing  effects  (Chen  174  
et  al.,  2016)  and   therefore  may  not  accurately   reflect   the  sensitivity  of  a  population  of  175  
HIV-­1   proviruses   to   transcriptional   activation   by  Vpx   or   to   silencing   by   FAM208A.   To  176  
address  the  effect  of  Vpx  and  FAM208A  on  on  a  population  of  proviruses  with  diverse  177  
integration   sites,   Jurkat   T   cells   were   transduced   with   an   HIV-­1   LTR   driven   reporter  178  
vector  (LTR-­gfp)  that  retains  complete  LTRs,  tat,  and  rev,  but  has  a  frameshift  mutation  179  
in  env,  an  ngfr   reporter  gene   in  place  of  nef,  and  gfp   in  place  of  gag,  pol,  vif,  and  vpr  180  
(Fig.  3d).  Four  wks  after  transduction  with  LTR-­GFP,  the  presence  of  latent  proviruses  181  
within  the  pool  of  Jurkat  cells  was  confirmed  by  reactivation  with  either  TNFα  or  TCR-­182  
stimulation   (Supplementary   Fig.   3b).   The   Jurkat   LTR-­gfp   cells   were   then   transduced  183  
with   vectors   expressing   SIVMAC251   Vpx   or   shRNA   targeting   FAM208A,   and   selected  184  
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with   puromycin.   Compared  with   control   cells,   vpx   or   FAM208A   knockdown   increased  185  
the  percentage  of  GFP+  cells,  whether  cells  were  treated  with  TNFα  or  not  (Figs  3e  and  186  
f).   Similar   results  were   obtained   in   three   independently   generated   biological   replicate  187  
experiments,  in  which  vpx  was  delivered  or  FAM208A  was  knocked  down,  from  four  to  188  
eight  wks  after  the  first  LTR-­GFP  transduction  (Fig.  3f).  Additionally,  expression  vectors  189  
for  SIVMND25440  Vpx,  SIVRCM02CM8081  Vpx,  SIVMND1GB1  Vpr,  or  SIVAGMTAN1  Vpr  all  190  
increased  GFP  expression   in  Jurkat  LTR-­gfp   cells   (Supplementary  Fig.  3c).  Together,  191  
these   experiments   demonstrate   that   FAM208A   contributes   to   the   transcriptional  192  
repression  of  clonal  or  polyclonal  LTR  reporter  lines,  and  that  primate  immunodeficiency  193  
viruses  counteract  this  activity  via  their  Vpx  and  Vpr  proteins.    194  
The   effect   of   Vpx   or   FAM208A   knockdown   on   spreading   infection   with  195  
replication-­competent  primate  immunodeficiency  viruses  was  tested  next.  Jurkat  T  cells  196  
transduced   to   express   SIVMAC251   vpx,   or   cells   transduced   with   control   vector,   were  197  
infected   with   HIV-­1-­ZsGreen,   a   replication-­competent   HIV-­1NL4-­3   clone,   that   encodes  198  
ZsGreen   in   place   of   nef   (Supplementary   Table   1).   Infection   was   monitored   by  199  
determining   the   percent   ZsGreen+   cells   with   flow   cytometry,   every   two   days   for   ten  200  
days.  Compared  with  the  control,  HIV-­1  replication  kinetics  was  accelerated  by  vpx  (Fig.  201  
4a).   In   similar   fashion,   HIV-­1   infection   of   Jurkat   cells   transduced   with   the   FAM208A  202  
knockdown  vector  resulted  in  faster  replication  kinetics  (Fig.  4b).  203  
HIV-­1   vpr   has   no   detectable   effect   on   HIV-­1   replication   in   tissue   culture  204  
spreading   infections  with   dividing   target   cells   (Miller   et   al.,   2017).   This   is   presumably  205  
related  to   the  cell  cycle  arrest   toxicity  (Chang  et  al.,  2004;;  Goh  et  al.,  1998;;  He  et  al.,  206  
1995;;  Re  et  al.,  1995),  and  selection  against  vpr   in   tissue  culture,  since   the  effects  of  207  
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vpr  on  HIV-­1  are  evident  when  proviral  expression  is  restricted  to  single  cycle  infection  208  
or   cells   are   arrested   with   aphidicolin   (Goh   et   al.,   1998).   Nonetheless,   vpr   offers   a  209  
selective  advantage  in  vivo  since  cloned  vpr  mutant  virus  was  repaired  when  virus  was  210  
injected  into  replication  permissive  chimps,  or  in  an  infected  person  (Goh  et  al.,  1998).  211  
SIVMAC239  does  not  replicate  in  Jurkat  cells  so  CEMx174  cells  were  used  to  test  212  
the  effect  of  FAM208A  and  vpx  on  replication  of  this  virus.  As  in  Jurkat  cells,  FAM208A  213  
knockdown   increased   HIV-­1   replication   kinetics   in   CEMx174   cells   (Fig.   4c).   Then,  214  
CEMx174   cells   transduced   with   FAM208A   or   control   knockdown   vectors   were  215  
challenged   with   SIVMAC239   or   SIVMAC239-­Δvpx   and   replication   was   assessed   by  216  
measuring   reverse   transcriptase   activity   in   the   supernatant.   In   the   absence   of   vpx,  217  
SIVMAC239   replicated   slower   than   the  wild-­type   virus   in   control   knockdown  CEMx174  218  
cells  (Fig.  4d).  This  delay  in  SIVMAC239-­Δvpx  replication  kinetics  was  not  observed  when  219  
FAM208A  was  knocked  down  (Fig.  4d).  Replication  of  HIV-­2GHΔvpx  was  undetectable  in  220  
control   knockdown  CEMx174  cells   (Fig.  4e).  However,  FAM208A  knockdown   rescued  221  
the  replication  of  HIV-­2GHΔvpx  to  the  level  of  wild-­type  HIV-­2GH  in  control  cells  (Fig.  4e).  222  
These   experiments   indicate   that   FAM208A   inhibits   primate   immunodeficiency   virus  223  
replication   and   that   Vpx   antagonizes   this   restriction,   resulting   in   expression   -­   or  224  
increased  expression  -­  from  integrated  proviruses,  permitting  virus  spread.  225  
The   experiments   reported   here   demonstrated   that   vpx   and   vpr   activate  226  
transcription  from  silenced  proviruses  and  that  this  activity  was  mimicked  by  knockdown  227  
of  each  of  the  HUSH  complex  components.  These  two  observations  were  then  shown  to  228  
be  linked  by  the  finding  that  Vpx  associated  with,  and  promoted  degradation  of  HUSH  229  
complex   protein   FAM208A,   in   a   DCAF1-­   and   proteasome-­dependent  manner.   Latent  230  
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provirus   activation   and   human   FAM208A   degradation   were   exhibited   by   a   broader  231  
range   of   primate   immunodeficiency   vpx   and   vpr   orthologues   than   are   capable   of  232  
degrading   human   SAMHD1,   perhaps   due   to   the   greater   conservation   and   essential  233  
nature   of   FAM208A.   Vpx   and   FAM208A   disruption   were   important   for   transcriptional  234  
activation  of  latent  HIV-­1  provirus  pools  and  for  the  ability  of  HIV-­1,  HIV-­2,  and  SIVMAC  235  
to   effectively   spread   through   cultured   CD4+   T   cells.   Further   understanding   of   the  236  
contributions  of  Vpx  and  Vpr  and  of  the  HUSH  complex  proteins,   in  concert  with  other  237  
transcriptional  silencing  mechanisms  targeting  HIV-­1,  is  hoped  to  inform  ongoing  efforts  238  
to  control  or  eliminate  proviruses  in  HIV-­1  infected  patients.     239  
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METHODS  240  
  241  
Plasmids.  Sequences  encoding  3xFLAG  N-­terminal-­tagged  Vpx  and  Vpr  proteins  were  242  
ordered  as  codon-­optimized,  gBlocks  Gene  Fragments  (Integrated  DNA  Technologies;;  243  
http://www.idtdna.com/)  and  cloned  into  either  the  pscALPS  vector  (Neagu  et  al.,  2009)  244  
for  transduction,  or  into  pcDNA3.1  for  transfection.  pAPM-­D4  is  a  truncated  derivative  of  245  
the   pAPM   lentivector   (Pertel   et   al.,   2011b)   that   expresses   the   puromycin  246  
acetyltransferase   and  miR30-­based   shRNA   from   the   SFFV   promoter.   Supplementary  247  
Table  1   lists  all  plasmids  used  here,  with  corresponding  addgene  accession  numbers,  248  
target   sites   used   in   particular   knockdown   vectors,   and   accession   numbers   for   all   the  249  
Vpx  and  Vpr  orthologues  tested  here.  All  plasmid  DNAs  and  sequences  are  available  at  250  
https://www.addgene.org/Jeremy_Luban/.  251  
  252  
Cell   culture.   Cells   were   cultured   at   37°C   in   5%   CO2   humidified   incubators   and  253  
monitored   for  mycoplasma   contamination   using   the  Mycoplasma  Detection   kit   (Lonza  254  
LT07-­318).  HEK293  cells  (ATCC)  were  used  for  viral  production  and  were  maintained  in  255  
DMEM   supplemented   with   10%   FBS,   20   mM   L-­glutamine   (ThermoFisher),   25   mM  256  
HEPES  pH  7.2   (SigmaAldrich),   1  mM  sodium  pyruvate   (ThermoFisher),   and  1x  MEM  257  
non-­essential   amino   acids   (ThermoFisher).   Jurkat   and   CEMx174   cells   (ATCC)   were  258  
cultured   in   RPMI-­1640   supplemented   with   10%   heat   inactivated   FBS,   20   mM   L-­259  
glutamine,  25  mM  HEPES  pH  7.2,  1  mM  sodium  pyruvate,  1x  MEM  non-­essential  amino  260  
acids  and  Pen/Strep  (ThermoFischer)  (RPMI-­FBS  complete).    J-­Lat  A1  cells  (Jordan  et  261  
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al.,  2003)  (NIH  AIDS  Reagent  Program,  catalogue  #9852,  donated  by  Eric  Verdin)  were  262  
cultured  in  RPMI-­FBS  complete  media.    263  
Leukopaks   were   obtained   from   anonymous,   healthy,   blood   bank   donors   (New  264  
York   Biologics,   Southhampton,   NY).   As   per   NIH   guidelines  265  
(http://grants.nih.gov/grants/policy/hs/faqs_aps_definitions.htm),  experiments  with  these  266  
cells  were  declared  non-­human  subjects   research  by   the  University  of  Massachusetts  267  
Medical   School   Institutional   Review   Board.   PBMCs   were   isolated   from   leukopaks   by  268  
gradient   centrifugation   on   Histopaque-­1077   (Sigma-­Aldrich).   CD4+   T   cells   were  269  
enriched   from   PBMCs   using   anti-­CD4   microbeads   (Miltenyi)   and   were   >95%   CD4+.  270  
CD4+  T  cells  were  cultured   in  RPMI-­FBS  complete  media   in   the  presence  of  50  U/mL  271  
hIL-­2  (NIH  AIDS  Reagent  Program,  catalogue  #136).  272  
  273  
Vector  production.  HEK293  cells  were  seeded  at  75%  confluency  in  6-­well  plates  and  274  
transfected  with  6.25  μL  Transit  LT1  lipid  reagent  (Mirus)   in  250  μL  Opti-­MEM  (Gibco)  275  
with  2.25  µg   total  plasmid  DNA.  Full   replicating  virus  was  produced  by   transfection  of  276  
2.25μg   of   the   indicated   plasmid.   Lenti-­GFP   reporters,   LTR-­GFP   reporter,   and   shRNA  277  
lentivectors  were  produced  by  transfection  of  the  lentivector,  psPAX2  gagpol expression 278  
plasmid, and the pMD2.G VSV G expression plasmid, at a DNA ratio of 4:3:1. Vpx 279  
containing SIV-VLPs were produced by transfection at a 7:1 plasmid ratio of SIV3+ to 280  
pMD2.G, and ∆Vpx SIV VLPs were produced the same way using SIV3+ ∆Vpx plasmid. 281  
12 hrs after transfection, media was changed to the specific media for the cells that 282  
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were to be transduced. Viral supernatant was harvested 2 days later, filtered through a 283  
0.45 µm filter, and stored at 4oC.  284  
  285  
Reverse  Transcriptase  assay.  Virions  in  the  transfection  supernatant  were  quantified  286  
by   a   PCR-­based   assay   for   reverse   transcriptase   activity   (Pertel   et   al.,   2011b).   5   μl  287  
transfection  supernatant  were   lysed   in  5  μL  0.25%  Triton  X-­100,  50  mM  KCl,  100  mM  288  
Tris-­HCl   pH   7.4,   and   0.4  U/μl  RNase   inhibitor   (RiboLock,   ThermoFisher).   Viral   lysate  289  
was  then  diluted  1:100  in  a  buffer  of  5  mM  (NH4)2SO4,  20  mM  KCl,  and  20  mM  Tris–HCl  290  
pH  8.3.  10  μL  was  then  added  to  a  single-­step,  RT  PCR  assay  with  35  nM  MS2  RNA  291  
(IDT)  as  template,  500  nM  of  each  primer  (5’-­TCCTGCTCAACTTCCTGTCGAG-­3’  and  292  
5’-­CACAGGTCAAACCTCCTAGGAATG-­3’),  and  hot-­start  Taq  (Promega)   in  a  buffer  of  293  
20  mM  Tris-­Cl   pH   8.3,   5  mM   (NH4)2SO4,   20  mM  KCl,   5  mM  MgCl2,   0.1  mg/ml   BSA,  294  
1/20,000  SYBR  Green   I   (Invitrogen),   and   200  μM  dNTPs.   The  RT-­PCR   reaction  was  295  
carried  out  in  a  Biorad  CFX96  cycler  with  the  following  parameters:  42°C  20  min,  95°C  2  296  
min,  and  40  cycles  [95°C  for  5  s,  60°C  5  s,  72°C  for  15  s  and  acquisition  at  80°C  for  5  297  
s].  3  part  vector  transfections  typically  yielded  106  RT  units/µL.  298  
    299  
Transductions.  For  generating  pools  of  shRNA  knockdown  Jurkat  and  CEMx174  lines,  300  
cells  were  plated  at  106   cells/mL   in  RPMI-­FBS  complete  and   transduced  with  107  RT  301  
units   of   viral   vector   per   106   cells,   followed   by   selection   with   1   μg/ml   puromycin  302  
(InvivoGen,   cat#   ant-­pr-­1).   To   generate   stable   gag-­gfp   expressing   Jurkat   cells,   cells  303  
were  transduced  as  for  shRNA  KD  above,  followed  by  selection  with  5  μg/mL  blasticidin  304  
(InvivoGen,  cat#  ant-­bl-­1)  at  day  3  after  transduction.    305  
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  306  
CD4+  T  cells  were  stimulated   in  RPMI-­FBS  complete,  with  50  U/ml   IL-­2  and  5  μg/mL  307  
PHA-­P  (Sigma,  cat#  L-­1668).  After  3  days,  T  cells  were  washed  and  replated  at  3  x  106  308  
cells/mL  in  RPMI-­FBS  complete,  with  50  U/ml  IL-­2.  Cells  were  transduced  with  108  RT  309  
units   of   viral   vector   per   106   cells   followed   by   selection   in   2   μg/mL   puromycin..   After  310  
selection,   cells   were   re-­plated   in   RPMI-­FBS   complete   with   50   U/ml   IL-­2   at   3   x   106  311  
cells/mL  in  RPMI-­FBS  complete  and  transduced  again  with  the  indicated  GFP  vectors,  312  
108  RT  units  of  viral  vector  per  106  cells.  Transduced  T  cells  were  analyzed  4-­5  days  313  
after  the  2nd  transduction.    314  
  315  
Lentiviral  Infections.  5  x  105  Jurkat  or  CEMx174  cells  were  incubated  with  5  x  107  RT  316  
units  of  HIV-­1NL4.3,  HIV-­2GH,  HIV-­2GHΔvpx,  SIVMAC239,  or  SIVMAC239Δvpx   virus   stocks  317  
produced  in  HEK-­293  cells  for  12  hrs  in  RPMI-­FBS  complete  media,  followed  by  a  wash  318  
in  media  and  replated  in  1  mL  of  media.  Cells  were  split  every  2-­3  days  and  analyzed.  319  
For  monitoring  of  HIV-­1  ZsGreen  infection,  when  cells  were  split,  aliquots  were  fixed  in  320  
BD  Cytofix  followed  by  analysis  of  GFP+  cells  by  flow  cytometry  to  determine  infection  321  
levels.  For  monitoring  of  SIV  and  HIV-­2   infections,  50  μL  aliquots  of  supernatant  were  322  
analyzed  for  RT  activity  using  the  above  described  RT  assay.    323  
  324  
Re-­activation   assays.  LTR-­driven  GFP   re-­activation   assays  were   performed  with   10  325  
ng/ml   hTNFα   (Invivogen,   cat#   rcyc-­htnf),   or   with   1   μg/ml   soluble   α-­CD3   and   α-­CD28  326  
antibody.   α-­CD3   antibody   (clone   OKT3)   and   α-­CD28   antibody   (clone   CD28.2)   were  327  
provided  by  Lisa  Cavacini  (MassBiologics,  Mattapan,  Massachusetts).  328  
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  329  
qRT-­PCR.   Total  RNA  was   isolated   from   Jurkat   cells   using  Trizol   reagent   followed   by  330  
purification  of  RNA  with  RNeasy  Plus  Mini  (Qiagen)  with  Turbo  DNase  (ThermoFisher)  331  
in   order   to   limit   DNA   contamination.   First-­strand   synthesis   used   Superscript   III   Vilo  332  
Master  mix   (Invitrogen)  with   random  hexamers.   qPCR  was   performed   in   20  μL   using  333  
SYBR  green  reagent  (Applied  Biosystems)  with  primers  designed  against  gag,  gfp,  and  334  
gapdh   for   normalization.   .   Amplification   was   on   a   CFX96   Real   Time   Thermal   Cycler  335  
(Bio-­Rad)  using  the  following  program:  95°C  for  10  min,  then  45  cycles  of  95°C  for  15  s  336  
and  60°C  for  60  s.  Cells  not   transduced  with  Lenti-­GFP  vector  were  used  as  negative  337  
control  and  the  housekeeping  gene  GAPDH  was  used  to  normalize  expression   levels.  338  
The   primer   sequences   used   were:   gag   primers   (Forward:   5’-­339  
GCTGGAAATGTGGAAAGGAA-­3’;;   Reverse:   5’-­AGTCTCTTCGCCAAACCTGA-­3’),   gfp  340  
primers   (Forward:   5’-­GCAGAGGTGAAGTTCGAAGG-­3’;;   Reverse:   5’-­341  
CCAATTGGTGTGTTCTGCTG-­3’),   gapdh   primers   (Forward:   5’-­342  
AGGGCTGCTTTTAACTCTGGT-­3’;;  Reverse:  5’-­CCCCACTTGATTTTGGAGGGA-­3’).  343  
    344  
Flow  cytometry.  Cells  were  fixed  in  BD  Cytofix  Buffer  prior  to  data  acquisition  on  a  BD  345  
C6  Accuri.  Data  was  analyzed  in  FlowJo.  346  
  347  
Western  Blot.  Cells  were  washed   in   PBS,   counted,   normalized   for   cell   number,   and  348  
lysed   directly   in   1x   SDS-­PAGE   sample   buffer.   Samples  were   run   on  NuPage   4-­12%  349  
Bis-­Tris   gels   followed   by   blotting   onto   nitrocellulose   membranes.   Primary   antibodies  350  
used:  FAM208A  (Atlas,  HPA00875),  MPHOSPH8  (Proteintech,  16796-­1-­AP),  PPHLN1  351  
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(Sigma,  HPA038902),  SETDB1  (Proteintech  11231-­1-­AP),  DCAF1  (Proteintech,  11612-­352  
1-­AP),   FLAG   (Novus,   NB600-­345),   FLAG   (Sigma,   F1804,   used   for   IP),   and   HA  353  
(Biolegend,  901501).    354  
  355  
Vpr  and  Vpx  phylogeny.  The  following  Vpr  and  Vpx  amino  acid  sequence  alignments  356  
were   obtained   from   the   Los   Alamos   National   Laboratories   (LANL)   HIV   sequence  357  
database:  2016  HIV-­1/SIVcpz  Vpr,  2016  HIV-­2/SIVsmm  Vpr,  2016  HIV-­2/SIVsmm  Vpx,  358  
2016   other   SIV  Vpr,   and   2016   other   Vpx.  Consensus   sequences  were   generated   for  359  
HIV-­1  group  M  subtypes  A,  B,  C,  D,  F,  G,  H,  I,  J,  and  those  designated  U  in  the  LANL  360  
database,   as   well   as   group   N.   A   master   alignment   was   scaffolded   from   the   above  361  
alignments  and  re-­aligned  by  hand.  Redundant  SIV  and  HIV-­2  Vpr  and  Vpx  sequences  362  
were   removed,  and   the  sequences  of   individual  HIV-­1   isolates  were   replaced  with   the  363  
consensus   sequences.   This  was   used   to   generate   a  master   phylogeny   using  RAxML  364  
8.2.11,   as   implemented   in   Geneious   with   gamma   LG   substitution   model   and   Rapid  365  
Bootstrapping  with  search  for  best  scoring  tree  algorithm.  This  master  tree  was  utilized  366  
to   identify   major   relationships   and   identify   a   reduced   number   of   sequences   to   retain  367  
while   maintaining   the   overall   phylogenic   structure.   Vpx   and   Vpr   sequences   from   the  368  
following   viral   isolates   were   retained:   HQ179987,   L20571,   M15390,   AF208027,  369  
AB731738,  KP890355,  M15390,  AF208027,  AB731738,  KP890355,  U58991,  M30931,  370  
L40990,   KJ461715,   AF301156,   U42720,   AY169968,   DQ373065,   DQ373064,  371  
DQ374658,   FJ919724,   AJ580407,   KM378563,   KM378563,   FJ424871,   M66437,  372  
AF468659,   AF468658,   AF188116,   M76764,   LC114462,   M27470,   AY159322,  373  
AY159322,   U79412,   U79412,   AY340701,   AY340700,   EF070329,   KF304707,  374  
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/293001doi: bioRxiv preprint first posted online Apr. 3, 2018; 
   18  
FM165200,   HM803690,   HM803689,   AF382829,   AF349680,   HM803690,   HM803689,  375  
AF349680,   U04005,   JX860432,   JX860430,   JX860426,   JX860432,   M83293,   M83293,  376  
AF131870,  AY523867,  AM182197,  AM713177,  U26942,  and  the  HIV-­1  group  M  clade  B  377  
consensus.   These   sequences   were   used   to   generate   a   phylogeny   using   the   same  378  
method  as  above.  Superfluous   taxa  were  pruned   from   this  phylogeny  using  Mesquite  379  
3.4  and  the  resulting  tree  was  visualized  in  FigTree  v1.4.3.    380  
  381  
Sampling.  At   least   three  biological  replicates  were  performed  for  all  experiments.  The  382  
screen   for   factors   mediating   silencing   of   the   Lenti-­GFP   vector   utilized   3   target  383  
sequences   for   each   candidate   gene.   Flow   cytometry   plots   in   the   figures   show  384  
representative  data  taken  from  experiments  performed  at  the  same  time.  HIV-­1,  HIV-­2,  385  
and  SIV  spreading  experiments  were  repeated  3  times  each  and  representative  data  of  386  
one  such  experiment  is  shown.    387  
  388  
Statistics.   Information   regarding   the   statistical   tests   utilized,   and   the   n   values,   are  389  
found   in   the   figure   legends.   Statistical   analysis   of   the   knockdown   screen   of   factors  390  
involved  in  silencing  of  Lenti-­GFP  was  analyzed  by  one-­way  ANOVA  with  Dunnett  post  391  
test   comparing   3   shRNA   target   sites   to   control   knockdown   conditions.   All   statistics  392  
presented  were  performed  using  PRISM  5.0  (GraphPAD  Software,  La  Jolla,  CA).       393  
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Figure  Legends  498  
  499  
Figure   1.   Diverse   primate   immunodeficiency   virus   vpx   and   vpr   orthologues   activate  500  
provirus   transcription,   whether   delivered   before,   during,   or   after   reporter   provirus  501  
integration.  502  
a,   Schematic   of   experimental   protocol   in   (b).   b,   Flow   cytometry   plot   showing   percent   GFP+  503  
Jurkat  cells  after  sequential  transduction  with  the  indicated  lentivectors,  followed  by  exposure  to  504  
the  indicated  VLPs.  c,d,  Histogram  of  flow  cytometry  signal  in  Jurkat  cells  transduced  with  gfp-­505  
reporter   virus,  and  either  exposed   to   the   indicated  VLPs   (c),   or   transduced  with   the   indicated  506  
vectors  (d).  e,  Phylogenetic  tree  showing  evolutionary  relationship  of  Vpx  and  Vpr  proteins.  The  507  
transactivation   activity   of   Jurkat   reporter   lines,   tested   as   in   (d),   and   human   SAMHD1  508  
degradation  activity   (Lim  et  al.,  2012),  are   indicated.  ∅ indicates Vprs   that  were   too   toxic   (G2  509  
arrest)  for  assessment.  All  data  shown  is  representative  of  at  least  three  biological  replicates.    510  
  511  
Figure  2.  Vpx  activates  provirus  transcription  by  degrading  HUSH  complex  components  512  
a,   Jurkat   cells   transduced   with   shRNA-­puroR   vectors   targeting   the   indicated   genes   were  513  
selected  with  puromycin,  transduced  with  Lenti  2-­Δvpx,  and  analyzed  5  days  later.  Plot  depicts  514  
GFP  signal  in  knockdown  lines  relative  to  Jurkats  bearing  SIVMAC251  vpx  (mean  ±  S.E.M.,  n=3  515  
shRNA  target  sites).  *,  P<0.05  as  determined  by  1-­way  ANOVA  with  Dunnett  post-­test,  relative  516  
to   luciferase   knockdown   control.   b,   Jurkat   cells   were   transduced   with   the   indicated   shRNA-­517  
puroR  vectors  and  selected  with  puromycin.  Resistant  cells  were  transduced  with  vpx+  or  Δvpx  518  
Lenti   2   vector,   and   analyzed   for   GFP   expression   7   days   later.   c,   Immunoblot   analysis   for  519  
components  of  the  HUSH  complex  in  Jurkat  cells  expressing  shRNA  constructs  used  in  (b).  d,  520  
CD4+  T  cells  were  activated  for  3  days  with  PHA  and  then  transduced  and  assayed  as  in  (b).  e,  521  
Immunoblot  analysis  of  Jurkat  lines  transduced  to  express  vpx  from  SIVMAC251,  SIVRCMNG411,  522  
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SIVMND25440,   or   control.   f,   Levels   of   HUSH   components   in   (e)   shown   as   shRNA   treated  523  
condition   relative   to   control.   g,   FAM208A,   DCAF1,   and   Actin   immunoblot   of   Jurkat   cells  524  
transduced  with   DCAF1   shRNA-­puroR   vector   or   control,   that   were   treated  with   Vpx+   or   ΔVpx  525  
VLPs   for   18   hrs.   h,   HEK293   cells   were   co-­transfected   with   HA-­FAM208A   and   the   indicated  526  
FLAG-­Vpx   constructs.   18   hrs   after   transfection,   cells   were   either   exposed   to   proteasome  527  
inhibitor  PR171  or  left  untreated.  8  hrs  after  inhibitor  treatment  cells  were  lysed,  FLAG-­Vpx  was  528  
immunoprecipitated,   and   immunoblotted   for   FLAG-­Vpx   and   HA-­FAM208A.   Immunoblotting   of  529  
input  lysates  are  shown  below.  530  
  531  
Figure  3.  The  HIV-­1  LTR  is  activated  by  Vpx  or  disruption  of  FAM208A  532  
a,  Schematic  of   the  HIV-­1  minigenome   integrated   in   the  J-­Lat  A1   line.  b,   J-­Lat  A1  cells  were  533  
transduced  with  Lenti  1  encoding  SIVMAC251  vpx  or  Δvpx  control,  or  with  lentivectors  expressing  534  
shRNA   targeting   FAM208A   or   luciferase   control.   Transduced   cells   were   selected   with  535  
puromycin,  and  activated  for  24  hrs  with  10  ng/ml  of  TNFα.  Representative  GFP  signal  by  flow  536  
is   shown.  c,   Quantification   of   results   from   (b)   and   additional   replicates   (mean  ±   S.E.M.,   n=3  537  
independent  experiments).  *,  P<0.02  d,  Schematic  of  the  LTR-­gfp  provirus  used  to  analyze  HIV-­538  
1  LTR  driven  gfp  expression  in  pools  of  cells.  e,  Jurkat  cells  transduced  with  LTR-­gfp  were  kept  539  
in   culture   for   4   wks   and   then   transduced   and   assessed   by   flow   cytometry,   as   in   (b).   f,  540  
Quantification  of  results  from  (e)  (mean  ±  S.E.M.,  n=4  independent  experiments)    *,  P<0.02  541  
  542  
Figure   4.   Vpx   counteracts   FAM208A   restriction   of   HIV-­1,   SIVMAC239,   or   HIV-­2GH,   during  543  
spreading  infection  in  CD4+  T  cells.  544  
a,b,   Replication   of   HIV-­1-­ZsGreen   in   Jurkat   cells   transduced   with   SIVMAC251   vpx   or  545  
control  (a),  or  with  lentivectors  expressing  shRNA  targeting  FAM208A  or  Luc  control  (b).  546  
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Replication   kinetics   was   measured   by   flow   cytometry   for   ZsGreen+   cells.   c,d,e,  547  
Spreading   infection  of  HIV-­1-­ZsGreen  (c),  SIVMAC239  or  SIVMAC239∆vpx (d),  and  HIV-­548  
2GH  or  HIV-­2GH ∆vpx  virus   in  CEMx174  cells   transduced  with  FAM208A  or  Luc  control  549  
shRNA.      Spread   of   HIV-­1-­ZsGreen   was   assessed   by   flow   cytometry   as   in   (a),   while  550  
spread  of  SIVmac239  (b)  and  HIV-­2GH  (c)  was  assessed  by  measuring  the  accumulation  551  
of   reverse   transcriptase   (RT)   activity   in   the   supernatant.   All   data   is   representative   of  552  
three  repeat  experiments.    553  
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